WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) said it has been added to the Nasdaq Biotechnology Index, a move that places the clinical-stage biopharmaceutical company among a select group of publicly traded biotech and pharmaceutical firms tracked by one of the sector’s most closely watched benchmarks.
The inclusion became effective at the close of trading on Friday, December 19, 2025. Membership in the index requires companies to meet specific criteria, including minimum market capitalization, trading liquidity, and time as a public company. The index is reviewed annually each December and is calculated using a modified capitalization-weighted methodology.
Inclusion in the Nasdaq Biotechnology Index can increase a company’s visibility among institutional investors, particularly those that track or benchmark against the index through exchange-traded funds and other passive investment vehicles. Companies added to the index may see increased trading activity as a result of portfolio rebalancing.
Aclaris is developing a pipeline of drug candidates aimed at immuno-inflammatory diseases, targeting conditions where existing treatments are limited or inadequate. The company’s portfolio spans multiple stages of development and is supported by what it describes as a broad research and development platform.
For Aclaris, the index addition represents a symbolic step as it continues to advance its pipeline and compete for capital in a crowded biotechnology market. The company said it remains focused on progressing its programs toward clinical and regulatory milestones while addressing areas of high unmet medical need.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.